Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Sellas Life Sciences Group, Inc.

NASDAQ: SLS · Life Sciences · 3 alerts · CIK 1390478

Share price
$7.47Close, Nov 16
Market cap
$1.52B
Shares outstanding
203.86MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Sellas Life Sciences Group, Inc. filings on SEC EDGAR ↗

7:15 AM ET 8-K
Clinical Trial Data

Sellas Life Sciences Group Clinical Trial Data

SELLAS announced positive topline results from its pivotal Phase 3 REGAL trial of galinpepimut-S (GPS) in patients with acute myeloid leukemia (AML). The trial met its primary endpoint of overall survival, showing a 41% reduction in the risk of death with a median OS of 24.0 months for GPS versus 14.7 months for best available treatment. The company plans to meet with the FDA to discuss the regulatory path forward for a Biologics License Application (BLA) submission.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.